The Carlyle Group has appointed Jesse Wu, former chairman of Johnson & Johnson China and former worldwide chairman of the Johnson & Johnson Consumer Group, as a senior advisor to the group’s Asia buyout team.
“Having been in the healthcare industry for almost three decades, I see fundamental changes happening in this space, ranging from changing demographic trends to more favorable regulatory reforms, as well as exciting, new technologies and treatments,” says Jesse Wu in an announcement.
Carlyle’s buyout team in Asia has been active investing in healthcare companies, with more than US$1.3 billion of equity invested in seven companies across the region.
Wu joined Johnson & Johnson in 1989 and served as chairman of Johnson & Johnson China and as a member of the company’s management committee from 2013 to 2016.
During his 26-year tenure at Johnson & Johnson, Wu served across multiple roles, including as worldwide chairman of the Johnson & Johnson Consumer Group and company group chairman for Global Markets.
Carlyle’s healthcare investments include Meinian Onehealth, Zhongmei Healthcare, MicroPort Scientific Corporation, and Haier Bio-Medical and Laboratory Products in China.
In India, Carlyle invested in Global Health and Metropolis Healthcare. It also backed Healthscope in Australia.
Globally, Carlyle has invested more than US$8.4 billion of equity in over 50 investments in the healthcare sector.